Northwest Biotherapeutics traded at $0.64 this Friday March 24th, decreasing $0.003 or 0.47 percent since the previous trading session. Looking back, over the last four weeks, Northwest Biotherapeutics lost 4.66 percent. Over the last 12 months, its price fell by 10.74 percent. Looking ahead, we forecast Northwest Biotherapeutics to be priced at 0.57 by the end of this quarter and at 0.52 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
Daily Change

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Peers Price Day Year
Eisai 7,167.00 -22.00 -0.31% 20.11%
Agenus 1.49 0.01 0.68% -44.81%
AstraZeneca 11,068.00 70.00 0.64% 12.45%
Bristol-Myers Squibb 67.68 0.70 1.05% -7.64%
Celldex Therapeutics 36.56 1.46 4.16% 6.50%
CTI Biopharma 4.30 0 0% -17.78%
CytrRx Corporation 0.08 -0.004 -4.75% -78.23%
Plus Therapeutics, Inc. 0.27 -0.01 -2.44% -72.78%
Infinity Pharmaceuticals 0.20 0.01 4.17% -79.80%
Merck & Co 104.80 0.57 0.55% 28.84%
Mirati Therapeutics 39.10 0.33 0.85% -51.22%
Northwest Biotherapeutics 0.64 -0.003 -0.47% -10.74%
Pfizer 40.39 0.21 0.52% -23.47%
Roche Holding 258.25 -0.10 -0.04% -31.08%

Indexes Price Day Year
USND 11824 36.56 0.31% -16.55%
US2000 1735 14.63 0.85% -16.51%

Northwest Biotherapeutics
Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to cover all solid tumor cancers in which the tumors can be surgically removed. It is on going Phase III trial for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct is being studied in a 60-patient Phase I/II trial for all types of inoperable solid tumors. The 40-patient Phase I stage of the trial has been completed. The Company is working on preparations for Phase II trials of DCVax-Direct. The Company also offers a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system, including T cells, B cells and antibodies and natural killer cells, among others to attack cancer cells to attack their cancer.